Patents by Inventor M. Amin Khan

M. Amin Khan has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Spiro-lactam and bis-spiro-lactam NMDA receptor modulators and uses thereof
    Patent number: 11028095
    Abstract: Disclosed are compounds having potency in the modulation of NMDA receptor activity. Such compounds can be used in the treatment of conditions such as depression and related disorders. Orally delivered formulations and other pharmaceutically acceptable delivery forms of the compounds, including intravenous formulations, are also disclosed.
    Type: Grant
    Filed: August 1, 2017
    Date of Patent: June 8, 2021
    Assignee: Aptinyx Inc.
    Inventor: M. Amin Khan
  • SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF
    Publication number: 20210155632
    Abstract: Disclosed are compounds having enhanced potency in the modulation of NMDA receptor activity. Such compounds are contemplated for use in the treatment of conditions such as depression and related disorders. Orally available formulations and other pharmaceutically acceptable delivery forms of the compounds, including intravenous formulations, are also disclosed.
    Type: Application
    Filed: July 2, 2020
    Publication date: May 27, 2021
    Inventors: John A. Lowe, III, M. Amin Khan
  • METHODS OF TREATING PAINFUL DIABETIC PERIPHERAL NEUROPATHY
    Publication number: 20210139489
    Abstract: Provided herein are methods of treating painful diabetic peripheral neuropathy, such as advanced painful DPN, in a patient by administering to the patient an effective amount of NYX-2925 or a pharmaceutically acceptable salt thereof. Also provided are crystalline forms of 3-hydroxy-2-(5-isobutyryl-1-oxo-2,5-diazaspiro[3,4]octan-2-yl)butanamide.
    Type: Application
    Filed: November 10, 2020
    Publication date: May 13, 2021
    Inventors: Torsten M. Madsen, M. Amin Khan, Mohsen Arghavani, Phil Bauer, Eduardo Mar
  • Spiro-lactam NMDA receptor modulators and uses thereof
    Patent number: 10961189
    Abstract: Disclosed are compounds having potency in the modulation of NMDA receptor activity. Such compounds can be used in the treatment of conditions such as depression and related disorders. Orally delivered formulations and other pharmaceutically acceptable delivery forms of the compounds, including intravenous formulations, are also disclosed.
    Type: Grant
    Filed: August 1, 2017
    Date of Patent: March 30, 2021
    Assignee: Aptinyx Inc.
    Inventor: M. Amin Khan
  • SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF
    Publication number: 20210047324
    Abstract: Disclosed are compounds having potency in the modulation of NMDA receptor activity. Such compounds can be useful in the treatment of conditions such as depression and related disorders as well as other disorders.
    Type: Application
    Filed: January 31, 2019
    Publication date: February 18, 2021
    Inventor: M. Amin Khan
  • Spiro-lactam NMDA receptor modulators and uses thereof
    Patent number: 10918637
    Abstract: Disclosed are compounds having potency in the modulation of NMDA receptor activity. Such compounds can be used in the treatment of conditions such as depression and related disorders. Orally delivered formulations and other pharmaceutically acceptable delivery forms of the compounds, including intravenous formulations, are also disclosed.
    Type: Grant
    Filed: August 1, 2017
    Date of Patent: February 16, 2021
    Assignee: Aptinyx Inc.
    Inventor: M. Amin Khan
  • SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF
    Publication number: 20210040095
    Abstract: Disclosed are compounds having potency in the modulation of NMDA receptor activity. Such compounds can be used in the treatment of conditions such as depression and related disorders as well as other disorders.
    Type: Application
    Filed: January 31, 2019
    Publication date: February 11, 2021
    Inventor: M. Amin Khan
  • NMDA receptor modulators and uses thereof
    Patent number: 10906913
    Abstract: Disclosed are compounds having enhanced potency in the modulation of NMDA receptor activity. Such compounds are contemplated for use in the treatment of diseases and disorder such as learning, cognitive activities, and analgesia, particularly in alleviating and/or reducing neuropathic pain. Orally available formulations and other pharmaceutically acceptable delivery forms of the compounds, including intravenous formulations, are also disclosed.
    Type: Grant
    Filed: October 17, 2017
    Date of Patent: February 2, 2021
    Assignee: Northwestern University
    Inventors: M. Amin Khan, Joseph R. Moskal, Paul Wood
  • SPIRO-LACTAM NMDA MODULATORS AND METHODS OF USING SAME
    Publication number: 20210002279
    Abstract: Disclosed are compounds having potency in the modulation of NMDA receptor activity. Such compounds can be used in the treatment of conditions such as depression and related disorders. Orally delivered formulations and other pharmaceutically acceptable delivery forms of the compounds, including intravenous formulations, are also disclosed.
    Type: Application
    Filed: February 4, 2020
    Publication date: January 7, 2021
    Inventor: M. Amin Khan
  • SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF
    Publication number: 20200206189
    Abstract: Disclosed are compounds having enhanced potency in the modulation of NMDA receptor activity. Such compounds are contemplated for use in the treatment of conditions such as depression and related disorders. Orally available formulations and other pharmaceutically acceptable delivery forms of the compounds, including intravenous formulations, are also disclosed.
    Type: Application
    Filed: August 9, 2019
    Publication date: July 2, 2020
    Inventors: John A. Lowe, III, M. Amin Khan
  • SPIRO-LACTAM AND BIS-SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF
    Publication number: 20200181159
    Abstract: Disclosed are compounds having potency in the modulation of NMDA receptor activity. Such compounds can be used in the treatment of conditions such as depression and related disorders. Orally delivered formulations and other pharmaceutically acceptable delivery forms of the compounds, including intravenous formulations, are also disclosed.
    Type: Application
    Filed: August 1, 2017
    Publication date: June 11, 2020
    Inventor: M. Amin Khan
  • SPIRO-LACTAM NMDA MODULATORS AND METHODS OF USING SAME
    Publication number: 20190330209
    Abstract: Disclosed are compounds having potency in the modulation of NMDA receptor activity. Such compounds can be used in the treatment of conditions such as depression and related disorders. Orally delivered formulations and other pharmaceutically acceptable delivery forms of the compounds, including intravenous formulations, are also disclosed.
    Type: Application
    Filed: November 21, 2018
    Publication date: October 31, 2019
    Inventor: M. Amin Khan
  • Spiro-lactam NMDA receptor modulators and uses thereof
    Patent number: 10441571
    Abstract: Disclosed are compounds having enhanced potency in the modulation of NMDA receptor activity. Such compounds are contemplated for use in the treatment of conditions such as depression and related disorders. Orally available formulations and other pharmaceutically acceptable delivery forms of the compounds, including intravenous formulations, are also disclosed.
    Type: Grant
    Filed: May 2, 2018
    Date of Patent: October 15, 2019
    Assignee: Aptinyx Inc.
    Inventors: John A. Lowe, III, M. Amin Khan
  • Spiro-lactam NMDA receptor modulators and uses thereof
    Patent number: 10441572
    Abstract: Disclosed are compounds having enhanced potency in the modulation of NMDA receptor activity. Such compounds are contemplated for use in the treatment of conditions such as depression and related disorders. Orally available formulations and other pharmaceutically acceptable delivery forms of the compounds, including intravenous formulations, are also disclosed.
    Type: Grant
    Filed: May 2, 2018
    Date of Patent: October 15, 2019
    Assignee: Aptinyx Inc.
    Inventors: John A. Lowe, III, M. Amin Khan
  • SPIRO-LACTAM NMDA MODULATORS AND METHODS OF USING SAME
    Publication number: 20190194200
    Abstract: Disclosed are compounds having potency in the modulation of NMDA receptor activity. Such compounds can be used in the treatment of conditions such as depression and related disorders. Orally delivered formulations and other pharmaceutically acceptable delivery forms of the compounds, including intravenous formulations, are also disclosed.
    Type: Application
    Filed: August 1, 2017
    Publication date: June 27, 2019
    Applicant: Aptinyx Inc.
    Inventor: M. Amin KHAN
  • SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF
    Publication number: 20190177334
    Abstract: Disclosed are compounds having potency in the modulation of NMDA receptor activity. Such compounds can be used in the treatment of conditions such as depression and related disorders. Orally delivered formulations and other pharmaceutically acceptable delivery forms of the compounds, including intravenous formulations, are also disclosed.
    Type: Application
    Filed: August 1, 2017
    Publication date: June 13, 2019
    Inventor: M. Amin Khan
  • SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF
    Publication number: 20190175588
    Abstract: Disclosed are compounds having potency in the modulation of NMDA receptor activity. Such compounds can be used in the treatment of conditions such as depression and related disorders. Orally delivered formulations and other pharmaceutically acceptable delivery forms of the compounds, including intravenous formulations, are also disclosed.
    Type: Application
    Filed: August 1, 2017
    Publication date: June 13, 2019
    Inventor: M. Amin Khan
  • Spiro-lactam NMDA receptor modulators and uses thereof
    Patent number: 10316041
    Abstract: Disclosed are compounds having enhanced potency in the modulation of NMDA receptor activity. Such compounds are contemplated for use in the treatment of conditions such as depression and related disorders. Orally available formulations and other pharmaceutically acceptable delivery forms of the compounds, including intravenous formulations, are also disclosed.
    Type: Grant
    Filed: June 16, 2017
    Date of Patent: June 11, 2019
    Assignee: Aptinyx Inc.
    Inventors: John A. Lowe, III, M. Amin Khan
  • SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF
    Publication number: 20190161442
    Abstract: Disclosed are compounds having potency in the modulation of NMDA receptor activity. Such compounds can be used in the treatment of conditions such as depression and related disorders. Orally delivered formulations and other pharmaceutically acceptable delivery forms of the compounds, including intravenous formulations, are also disclosed.
    Type: Application
    Filed: August 1, 2017
    Publication date: May 30, 2019
    Inventor: M. Amin Khan
  • NDMA RECEPTOR MODULATORS AND USES THEREOF
    Publication number: 20190135862
    Abstract: Disclosed are compounds having enhanced potency in the modulation of NMDA receptor activity. Such compounds are contemplated for use in the treatment of diseases and disorders, such as learning, cognitive activities, and analgesia, particularly in alleviating and/or reducing neuropathic pain. Orally available formulations and other pharmaceutically acceptable delivery forms of the compounds, including intravenous formulations, are also disclosed.
    Type: Application
    Filed: July 6, 2018
    Publication date: May 9, 2019
    Inventors: M. Amin Khan, Joseph Moskal